Clinic Software← All companies
Arialys Therapeutics
StageSeed
Raised$58M
Employees11
LocationLa Jolla, CA
About
We now know that immune cells – not only in the body’s periphery but especially in the brain – can produce autoantibodies that cause severe neurological and psychiatric diseases. Founded to explore the latest discoveries in autoimmune neuropsychiatry, Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease.
Product
- Regulatory
- IND clearance for ART5803; open-label Phase 2 study; FDA rare pediatric disease designation (ART5803) for anti-NMDA receptor encephalitis
Founders
- Jay Lichter — President and CEO, Cofounder
- Mitsuyuki “Mickey” Matsumoto — Scientific Founder and CSO
- BT Slingsby — Cofounder and Director
- Ed Hurwitz — Cofounder and Director
- Avalon BioVentures — Founding investor/organization
- Catalys Pacific — Founding investor/organization
- MPM BioImpact — Founding investor/organization
Categories
Products
ART5803
Key features
precision medicine targeting pathogenic autoantibodies in the brainNMDAR-targeted therapyopen-label Phase 2 studyIND clearance for randomized Phase 2 study
Technologies
structure-based designautoimmune neuropsychiatry targeting antibodiesart5803 therapy
Target conditions
anti-NMDA receptor encephalitisautoimmune neuropsychiatric diseaseneuropsychiatric disorders driven by autoimmune disease
Care settings
clinicalresearchlab
Awards
FDA Rare Pediatric Disease Designation (ART5803) for anti-NMDA receptor encephalitis
Investors
Avalon BioVenturesCatalys PacificMPM BioImpactJohnson & Johnson Innovation – JJDC, Inc.Alexandria Venture Investments
News
- Arialys - 2026 Company Profile, Team, Funding & Competitors · 2026-05-05T00:00:00.000Z
- Arialys Therapeutics: Funding, Team & Investors | Startup Intros · 2026-04-16T00:00:00.000Z
- Arialys Therapeutics Announces U.S. FDA Fast Track Designation for ART5803, the First Precision Therapeutic Candidate in Development for the Treatment of Anti-NMDA Receptor Encephalitis · 2026-07-09T13:00:00.000Z
- Arialys presents promising data for IgG1 antibody treatment · 2025-06-20T09:02:44.000Z
- Arialys Therapeutics Announces First ANRE Patient Treated with ART5803 in Open-Label Phase 2 Study and FDA Clearance of IND for Randomized Phase 2 Study - BioSpace · 2026-06-15T14:54:06.000Z
- Arialys' Precision Drug Offers New Hope for Rare Autoimmune Brain Disease - BriefGlance.com · 2026-06-15T13:00:00.000Z
